Log in

Relevant bibliographies by topics / Oral iron chelator drug

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Oral iron chelator drug'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Oral iron chelator drug.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Oral iron chelator drug"

1

Neufeld, Ellis J. "Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions." Blood 107, no. 9 (2006): 3436–41. http://dx.doi.org/10.1182/blood-2006-02-002394.

Full text

Abstract:

For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation. Despite dramatic gains in life expectancy in the deferoxamine era for patients with transfusion-dependent anemias, the leading cause of death for young adults with thalassemia major and related disorders has been cardiac disease from myocardial iron deposition. Strategies to reduce cardiac disease by improving chelation regimens have been of the highest priority. These strategies have included development of novel oral iron chelators to improve compliance, improved

APA, Harvard, Vancouver, ISO, and other styles

2

Cabantchik, Z. I., G. Link, H. Glickstein, et al. "Deferasirox (Exjade®, ICL670): A Journey into Labile Iron Centers of Living Cardiomyocytes." Blood 106, no. 11 (2005): 824. http://dx.doi.org/10.1182/blood.v106.11.824.824.

Full text

Abstract:

Abstract Introduction and Aims: Iron toxicity that prevails in iron overload is associated with forms of labile cell iron (LCI) that appear in tissues such as heart, endocrine glands and liver. The primary goal of chelation is to reduce LCI appearance by preventing the entry of labile plasma iron into cells and by chelating LCI. The present study was aimed at evaluating the capacity of the novel oral iron chelator deferasirox (a) to access cardiomyocytes and chelate LCI in the cell organelles harboring labile iron and thereby prevent its involvement in reactive oxidant species (ROS) formation

APA, Harvard, Vancouver, ISO, and other styles

3

Nathan, David G. "Oral iron chelation: new drug, old rules." Blood 111, no. 2 (2008): 483–84. http://dx.doi.org/10.1182/blood-2007-11-123349.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Neufeld, Ellis J. "Update on Iron Chelators in Thalassemia." Hematology 2010, no. 1 (2010): 451–55. http://dx.doi.org/10.1182/asheducation-2010.1.451.

Full text

Abstract:

Abstract Over the past four decades, there have been dramatic improvements in survival for patients with thalassemia major due in large measure to improved iron chelators. Two chelators are approved for use in the United States and Canada, parenteral deferoxamine and oral deferasirox. Three are available in much of the rest of the world, where oral deferiprone is also approved (in the United States, deferiprone is only available in studies, for emergency use, or on a “compassionate-use” basis). Many trials and worldwide clinical experience demonstrate that each of the three drugs can chelate a

APA, Harvard, Vancouver, ISO, and other styles

5

Barua, Tanuka, Golam Mohammed Tayab Ali, Rana Chowdhury, Dhananjoy Das, Showrov Barua Chowdhury, and Mahmud Ahmed Chowdhury Arzu. "Barriers to Adherence to Iron Chelation Therapy in Thalassemia Patients." Chattagram Maa-O-Shishu Hospital Medical College Journal 20, no. 2 (2021): 45–49. http://dx.doi.org/10.3329/cmoshmcj.v20i2.56473.

Full text

Abstract:

Background: Thalassemias are the most common inheritable blood disorders requiring regular blood transfusions and iron chelating therapy. Non-adherence to iron chelation therapy increases complications and is a problem in treating thalassemia. To assess the reasons of non-adherence to iron chelating drug in treating thalassemia. Materials and methods: This descriptive cross-sectional study was carried out in the thalassemia ward of Chattogram Maa Shishu-O-General Hospital, Chattogram from July, 2013 to June, 2014. 70 thalassemia patients aged 2-18 years previously treated with iron chela

APA, Harvard, Vancouver, ISO, and other styles

6

Hoffbrand, A. Victor, Ali Taher, and Maria Domenica Cappellini. "How I treat transfusional iron overload." Blood 120, no. 18 (2012): 3657–69. http://dx.doi.org/10.1182/blood-2012-05-370098.

Full text

Abstract:

Abstract Patients with β-thalassemia major (TM) and other refractory anemias requiring regular blood transfusions accumulate iron that damages the liver, endocrine system, and most importantly the heart. The prognosis in TM has improved remarkably over the past 10 years. This improvement has resulted from the development of magnetic resonance imaging (MRI) techniques, especially T2*, to accurately measure cardiac and liver iron, and from the availability of 3 iron-chelating drugs. In this article we describe the use of MRI to determine which adult and pediatric patients need to begin iron chel

APA, Harvard, Vancouver, ISO, and other styles

7

Delea, T. E., K. El Ouagari, and O. Sofrygin. "Cost of Current Iron Chelation Infusion Therapy and Cost-Effectiveness of Once-Daily Oral Deferasirox in Transfusion-Dependent Thalassemia Patients in Canada." Blood 108, no. 11 (2006): 3349. http://dx.doi.org/10.1182/blood.v108.11.3349.3349.

Full text

Abstract:

Abstract Background: Deferasirox (Exjade®) is a recently approved once-daily oral chelator that has been shown to produce reductions in liver iron concentrations and serum ferritin similar to those with infusional deferoxamine (Desferal®), in patients with β-thalassemia major or sickle cell disease (SCD) and chronic iron overload from blood transfusions. The objective of this study was to estimate the cost of deferoxamine administration in Canada and evaluate the cost-effectiveness of deferasirox versus deferoxamine for chronic iron overload from blood transfusions from the Ontario provincial

APA, Harvard, Vancouver, ISO, and other styles

8

Grady, Robert W., Maria Sitarou, Renzo Galanello, et al. "Efficacy of the Novel Oral Iron Chelator Deferitrin in Metabolic Iron Balance Studies." Blood 110, no. 11 (2007): 2775. http://dx.doi.org/10.1182/blood.v110.11.2775.2775.

Full text

Abstract:

Abstract Deferiprone (L1, Ferriprox) and deferasirox (ICL670, Exjade), two orally effective iron-chelating agents, have revolutionized the management of iron overload. Nonetheless, neither drug is effective in all patients, deferoxamine (DFO) still being the only drug capable of placing all affected individuals in net negative iron balance. Deferitrin (4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid, GT56-252), is a tridentate ligand with a demonstrated efficacy and an acceptable toxicity profile in preclinical evaluations in primates. In Phase 1 studies, it was well

APA, Harvard, Vancouver, ISO, and other styles

9

Nyffenegger, Naja, Anna Flace, Cédric Doucerain, Franz Dürrenberger та Vania Manolova. "The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia". International Journal of Molecular Sciences 22, № 2 (2021): 873. http://dx.doi.org/10.3390/ijms22020873.

Full text

Abstract:

In β-thalassemia, ineffective erythropoiesis leads to anemia and systemic iron overload. The management of iron overload by chelation therapy is a standard of care. However, iron chelation does not improve the ineffective erythropoiesis. We recently showed that the oral ferroportin inhibitor VIT-2763 ameliorates anemia and erythropoiesis in the Hbbth3/+ mouse model of β-thalassemia. In this study, we investigated whether concurrent use of the iron chelator deferasirox (DFX) and the ferroportin inhibitor VIT-2763 causes any pharmacodynamic interactions in the Hbbth3/+ mouse model of β-thalassem

APA, Harvard, Vancouver, ISO, and other styles

10

Basu, Tapasree, Bipul Kumar, Anil K. Shendge, et al. "An Indian Desert Shrub ‘Hiran Chabba’, Farsetia hamiltonii Royle, Exhibits Potent Antioxidant and Hepatoprotective Effect Against Iron- Overload Induced Liver Toxicity in Swiss Albino Mice." Current Drug Discovery Technologies 16, no. 2 (2019): 210–22. http://dx.doi.org/10.2174/1570163815666180418150123.

Full text

Abstract:

Background:Farsetia hamiltonii Royle, also known as Hiran Chabba grows in desert regions. It is widely used as folk medicine to treat joint pains, diarrhea and diabetes. However, its antioxidant and iron chelation abilities both in vitro and in vivo have not yet been investigated.Methods:The 70% methanolic extract of F. hamiltonii (FHME) was investigated for its free radical scavenging and iron chelation potential, in vitro. An iron-overload situation was established by intraperitoneal injection of iron-dextran in Swiss albino mice, followed by oral administration of FHME. Liver damage and ser

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Oral iron chelator drug"

1

Whiteside, Douglas P. "Evaluation of the oral iron chelator deferiprone in the white leghorn chicken and domestic pigeon." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp05/NQ61990.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hileti, Dona. "Biological and pharmacokinetic studies on the oral iron chelator 1, 2 dimethyl-3-hydroxpyrid-4-one." Thesis, University College London (University of London), 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.307678.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chang, Yu-Chien, and 張雨倩. "Preclinical study of oral iron chelator Deferasirox in combination with chemo-therapeutic drug in acute myeloid leukemia." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/27012354602367818085.

Full text

Abstract:

博士<br>國立中興大學<br>生命科學系所<br>104<br>Iron catalyzes the formation of mutagenic reactive oxygen species (ROS), which are critically involved in the whole process of cancer formation including cancer cell initiation, proliferation, metabolism, angiogenesis and metastasis. Recent evidence suggests iron chelators may work as a potential anti-tumor agent through disturbing the iron metabolism. Actually, there is an interesting case report showing that the iron chalation therapy with deferasirox, intended to treat transfusional iron overload initially, induced complete remission on a patient of refracto

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Oral iron chelator drug"

1

Stobie, Shannon Blaire. The novel oral iron chelator, L1, in acute and chronic iron overload. National Library of Canada, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Oral iron chelator drug"

1

Grahame-Smith, D. G., and J. K. Aronson. "The drug therapy of blood disorders." In Oxford Textbook of Clinical Pharmacology and Drug Therapy. Oxford University PressNew York, NY, 2002. http://dx.doi.org/10.1093/oso/9780192632340.003.0028.

Full text

Abstract:

Abstract The aims in treating iron deficiency anaemia are to remove the cause and to increase red cell mass by giving iron. The main causes of iron deficiency anaemia are listed in Table 28.1. Iron can be given orally or parenterally, and in almost all patients the oral route is satisfactory. Iron in oral formulations is in the ferrous form, since that is the form in which iron is absorbed, mostly from the upper jejunum. Normal dietary iron absorption is 1–2 mg from a dietary intake of 10–20 mg, balancing the daily losses, which are mainly from sloughing of cells from the gastrointestinal trac

APA, Harvard, Vancouver, ISO, and other styles

2

Mohan, Kiranjyoti. "Smart Polymeric Composites in Controlled Drug Delivery." In Smart Polymeric Nanocomposites: Synthesis and Applications. BENTHAM SCIENCE PUBLISHERS, 2025. https://doi.org/10.2174/9789815322040125010006.

Full text

Abstract:

A drug delivery system (DDS) is the mode by which a drug is incorporated inside the body to produce therapeutic effects at the desired pathological site. Common DDSs include capsules and tablets (through the oral route), intravenous injections, nasal and ocular drops, transdermal patches, ointments, gels, etc. The important criteria for an active pharmaceutical ingredient (API) to be effective are that it should be precise and specific for the site of interest, with minimal side effects. This is where the formulation of the drug becomes very important. Regulating the entry of the drug into the

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Oral iron chelator drug"

1

Kim, Jung-Lim, Han-Na Kang, Myoung Hee Kang, et al. "Abstract 4091: The oral iron chelator, deferasirox, induces apoptosis in myeloid leukemia cells through caspase-dependent activation." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4091.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!